Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.

about

Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010.Physiologically based and population PK modeling in optimizing drug development: A predict-learn-confirm analysis.

P2860

Q38560098-FC7A8AEF-81E9-4E29-A20A-2CC6BC8260D7 Q40882268-A88FDAB3-0EBA-4442-A98F-C3407D772FFA

P2860

Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.

Item

http://www.wikidata.org/entity/Q38287050

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Emerging areas of research in ...... s with chronic kidney disease.

@en

type

Item

label

Emerging areas of research in ...... s with chronic kidney disease.

@en

prefLabel

Emerging areas of research in ...... s with chronic kidney disease.

@en

P1476

Emerging areas of research in ...... s with chronic kidney disease.

@en

P2093

Anasuya Hazra

http://www.w3.org/2001/XMLSchema#string

David L Cutler

http://www.w3.org/2001/XMLSchema#string

Karen Rowland-Yeo

http://www.w3.org/2001/XMLSchema#string

Karthik Venkatakrishnan

http://www.w3.org/2001/XMLSchema#string

Michael A Tortorici

http://www.w3.org/2001/XMLSchema#string

Thomas D Nolin

http://www.w3.org/2001/XMLSchema#string

P2860

Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues.

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.

Clinical pharmacokinetics of clarithromycin.

Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives.

Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development.

Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology.

Assessing kidney function--measured and estimated glomerular filtration rate.

Drug-associated renal dysfunction and injury.

Epidemiology of anemia associated with chronic renal insufficiency.

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

P304

241-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.444

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25501531

http://www.w3.org/2001/XMLSchema#string

Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.

about

P2860

P2860

Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698